R-HCVAD regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} Rituximab-Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen ==Overview== {{PAGENAME}} refers to a regimen co..." |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|doxorubicin (Adriamycin)]], and [[dexamethasone]] used to treat some forms of [[mantle cell lymphoma]]. | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]], [[vincristine]], [[Doxorubicin|doxorubicin (Adriamycin)]], and [[dexamethasone]] used to treat some forms of [[mantle cell lymphoma]].<ref name="pmid16145068">{{cite journal| author=Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al.| title=High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 28 | pages= 7013-23 | pmid=16145068 | doi=10.1200/JCO.2005.01.1825 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16145068 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
| Line 21: | Line 20: | ||
==Indications== | ==Indications== | ||
* [[Mantle cell lymphoma]] | * [[Mantle cell lymphoma]]<ref name="pmid16145068">{{cite journal| author=Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al.| title=High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 28 | pages= 7013-23 | pmid=16145068 | doi=10.1200/JCO.2005.01.1825 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16145068 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 17:14, 31 March 2015
|
WikiDoc Resources for R-HCVAD regimen |
|
Articles |
|---|
|
Most recent articles on R-HCVAD regimen Most cited articles on R-HCVAD regimen |
|
Media |
|
Powerpoint slides on R-HCVAD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-HCVAD regimen at Clinical Trials.gov Trial results on R-HCVAD regimen Clinical Trials on R-HCVAD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-HCVAD regimen NICE Guidance on R-HCVAD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-HCVAD regimen Discussion groups on R-HCVAD regimen Patient Handouts on R-HCVAD regimen Directions to Hospitals Treating R-HCVAD regimen Risk calculators and risk factors for R-HCVAD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-HCVAD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
R-HCVAD regimen refers to a regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of mantle cell lymphoma.[1]
Regimen
RRituximab
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B; et al. (2005). "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine". J Clin Oncol. 23 (28): 7013–23. doi:10.1200/JCO.2005.01.1825. PMID 16145068.